Docket No.: PF-0049-2 DIV

REMARKS

Justification for the amendments is as follows. Claims 2, 3, and 11-13 are canceled above, and claims 1, 4-10, and 14-18 are pending.


The amendment to the specification at pages 35 through 43 of the specification replaces the Sequence Listing as filed with the Substitute Sequence Listing filed December 11, 1997, in prior U.S. application Serial No. 08/567,508, and referenced in the filing papers for the present application. (See page 1 of the transmittal for the present application.) The Substitute Sequence Listing properly identifies the MUSPTK1 sequence, described at page 5 of the specification and shown in Figures 2A, 2B, 2C, 2D, 2E, and 2F as originally filed, as SEQ ID NO:3, and identifies sequences XLR and XLF, which appear at page 21 of the specification as originally filed, as SEQ ID NO:4 and SEQ ID NO:5, respectively. These sequences do not constitute new matter as MUSPTK1, XLR, and XLF appear in the application as filed.

The Substitute Sequence Listing corrects an error in SEQ ID NO:2 in the Sequence Listing as originally filed. Specifically, the latter part of SEQ ID NO:2, starting around residue 990, appears to have been incorrectly translated. However, SEQ ID NO:2 was correct as shown in Figures 1A, 1B, 1C, 1D, 1E, and 1F as filed. Accordingly, SEQ ID NO:2 as it appears in the Substitute Sequence Listing accompanying this Amendment is correct. This corrected sequence is not new matter as the correct sequence was shown in Figures 1A, 1B, 1C, 1D, 1E, and 1F of the application as filed. Applicants apologize for any inconvenience that might have been caused by this error. Applicants note that SEQ ID NO:1 was correct in the application as filed in both Figures 1A, 1B, 1C, 1D, 1E, and 1F and in the Sequence Listing.

The amendments to the specification at page 5, lines 2 and 6, and page 20, line 24, are made to reflect the renumbering of the figures in the preparation of formal drawings. The remaining amendments to the specification are merely typographical or grammatical in nature.

The amendments to the drawings were made to clarify Figures 2A, 2B, 2C, 2D, and 2E, and 2F. Specifically, Figures 2A, 2B, 2C, 2D, 2E, and 2F as originally filed showed the alignment between HJAK2 (SEQ ID NO:2) and MUSPTK1 (GI 409584; SEQ ID NO:3), along with two consensus sequences generated by DNASTAR software, the multisequence alignment program used. Figures 2A, 2B, 2C, 2D, 2E, and 2F as amended show only the alignment

50634



between HJAK2 (SEQ ID NO:2) and MUSPTK1 (GI 409584; SEQ ID NO:3).

No new matter is added by any of these amendments.

If there are any questions regarding the above, the Examiner is invited to call Applicants' Agent at (650) 855-0555.

Respectfully submitted,

INCYTE PHARMACEUTICALS, INC.

Date: December 9, 1999

Susan K. Nather

Susan K. Sather Reg. No. 44,316

Direct Dial Telephone: (650) 845-4646

3174 Porter Drive Palo Alto, California 94304

Phone: (650) 855-0555 Fax: (650) 849-8886

50634

7

